About Genzyme
Genzyme is a Healthcare company based in Boston (United States) founded in 1996, and was acquired by Sanofi in February 2011. Biopharmaceutical products for rare genetic diseases are developed and supplied. Genzyme has completed 2 acquisitions, including Bioenvision and Ilex Oncology. Its Indian entity Genzyme India Private Limited reported revenue of ₹50 Lakh. Genzyme offers products and services including Vaccines, Medicines for Immunology, Neurology Medicines, and Consumer Healthcare Products. Its focus areas include Diversified Pharmaceuticals.
Company details
Genzyme Corporation is a fully owned subsidiary of Sanofi. It is focused on rare genetic diseases known as lysosomal storage disorders (LSDs). They have also expanded through both in-house development and strategic acquisitions and partnerships to other disease areas such as thyroid cancer and multiple sclerosis. The first orphan-drug for Genzyme that FDA approved was Ceredase, a drug for treating Gaucher disease. Other important drugs made by Genzyme are Renagel, used in treatment of dialysis patients, and Fabrazyme, used to treat patients with Fabrys disease. Other products in development are Tolevamer for Clostridium difficile colitis and Campath for Chronic lymphocytic leukemia.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Website genzyme.com
- Social LinkedIn YouTube
- Acquired by Sanofi (Feb 2011)
- Legal Name Genzyme India Private Limited
- Date of Incorporation 21 Nov, 2007
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹50 Lakh
FY 2018 · +20% YoY
- Indian entity net profit₹23.5 Lakh
FY 2018 · 47% margin
- Indian entity EBITDA₹36.4 Lakh
FY 2018 · 73% margin
- Investors
- Investments & AcquisitionsBioenvision
& 1 more
- Acquired bySanofi
(Feb 2011)
Associated legal entities of Genzyme
Genzyme operates through Genzyme India Private Limited (amalgamated). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2018) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Genzyme India Private Limited CIN U40300MH2007FTC256223 | Amalgamated | 21 Nov 2007 | Mumbai, Maharashtra | ₹0.5 Cr | 2 | View details |
Products & Services of Genzyme
Genzyme offers a comprehensive portfolio of products and services, including Vaccines, Medicines for Immunology, Neurology Medicines, and Consumer Healthcare Products.
Products that prevent diseases like influenza and meningitis.
Treatments targeting immune system disorders and related conditions.
Drugs for neurological conditions such as rare diseases and disorders.
Items for allergy, cold relief, and digestive health management.
Apps and channels of Genzyme
its YouTube channel Sanofi has 33K subscribers and 30 videos.
Videos from Genzyme
The most watched videos on Genzyme's YouTube channel, Sanofi (33K subscribers). Click a video to play it here.
More on Sanofi.
Investors in Genzyme
Genzyme has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France |
Investor details for Genzyme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Genzyme India Private Limited (Genzyme)
Genzyme India Private Limited is the primary company behind Genzyme. The board of Genzyme India Private Limited currently have 2 directors; the longest-serving is Rajaram Narayanan, appointed in 2018. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajaram Narayanan DIN 02977405 | Director | 01 Jan 2018 | 8 yrs 9 mo | Genzyme India Private Limited |
| Charles Alexis Maxime Billard DIN 08173583 | Director | 12 Jul 2018 | 8 yrs 3 mo | Genzyme India Private Limited |
Financials of Genzyme
Figures of Genzyme India Private Limited, the primary company behind Genzyme, for FY 2018. Revenue was ₹50 Lakh (+20% year on year). Net profit was ₹23.5 Lakh (47% margin). EBITDA was ₹36.4 Lakh (73% margin). Revenue has grown at a compounded annual rate of -12% over three years.
- ₹50 LakhRevenue · FY 2018 · +20% YoY
- ₹23.5 LakhNet profit · 47% margin
- ₹36.4 LakhEBITDA · 73% margin
- ₹9.21 CrPaid-up capital
- -12%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Genzyme India Private Limited are on its company page.
Detailed financial statements for Genzyme
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genzyme
Genzyme has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bioenvision and Ilex Oncology.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Acquisition, development, and marketing of compounds and technologies for the treatment of cancer | bioenvision.com | New York, United States | 1996 | May 2007 | $345M | |
Monoclonal antibody therapies for B-cell chronic lymphocytic leukemia are developed. | ilexoncology.com | Antony, France | 2000 | Feb 2004 | $1B |
Complete acquisition details for Genzyme
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Genzyme
4 dated milestones of Genzyme across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Genzyme is founded.
- Acquisition Acquires Ilex Oncology.
- Acquisition Acquires Bioenvision.
- Exit Acquired by Sanofi.
Web traffic of Genzyme
Websites that share an audience with Genzyme (genzyme.com).
Websites whose visitors overlap most with Genzyme. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| amgen.com | 100% | 495.4K | #116,434 | View details | |
sanofi.us | sanofi.us | 100% | #672,567 | – | |
| novartis.com | 94% | 948.8K | #58,822 | View details | |
| pfizer.com | 92% | 1.9M | #24,984 | View details | |
| roche.com | 82% | 1.3M | #42,219 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 29 similar websites and full traffic analytics for Genzyme
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 29 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Genzyme (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genzyme
Complete news archive for Genzyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genzyme
Genzyme was founded in 1996.
Genzyme is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
The primary company behind Genzyme, Genzyme India Private Limited, reported revenue of ₹50 Lakh for FY 2018, up 20% year on year.
Genzyme Corporation is a fully owned subsidiary of Sanofi. It is focused on rare genetic diseases known as lysosomal storage disorders (LSDs). They have also expanded through both in-house development and strategic acquisitions and partnerships to other disease areas such as thyroid cancer and multiple sclerosis. The first orphan-drug for Genzyme that FDA approved was Ceredase, a drug for treating Gaucher disease. Other important drugs made by Genzyme are Renagel, used in treatment of dialysis patients, and Fabrazyme, used to treat patients with Fabrys disease. Other products in development are Tolevamer for Clostridium difficile colitis and Campath for Chronic lymphocytic leukemia.
Genzyme offers Vaccines, Medicines for Immunology, Neurology Medicines, and Consumer Healthcare Products.
Genzyme has made 2 acquisitions, including Bioenvision, and Ilex Oncology.
Genzyme has 1 investor. Key investors include Sanofi.
Genzyme operates through Genzyme India Private Limited.
Yes. Genzyme was acquired by Sanofi in February 2011.
The legal entities of Genzyme currently have 2 directors, including Charles Alexis Maxime Billard, Rajaram Narayanan.